Difference between revisions of "Part:BBa K4891018"
| Line 5: | Line 5: | ||
It is the key part that is responsible for optimizing metabolic network of the E. coli MG1655. Complicated metabolic flux usually leads to the inefficient production performance. With the disruption of the byproducts, intracellular PEP availability could be improved. | It is the key part that is responsible for optimizing metabolic network of the E. coli MG1655. Complicated metabolic flux usually leads to the inefficient production performance. With the disruption of the byproducts, intracellular PEP availability could be improved. | ||
| − | <!-- Add more about the biology of this part here | + | <!-- Add more about the biology of this part here --> |
===Usage and Biology=== | ===Usage and Biology=== | ||
| + | We engineered the shikimate pathway of E. coli MG1655 to efficiently accumulate SA. We knocked out ptsG, ldhA, adhE, poxB, and pta genes to achieve the production of precursor substance PEP. To increase intracellular E4P content, we overexpressed tktA and talB genes. To enhance product accumulation, we overexpressed aroG, aroB, aroD, and aroE genes, while knocking down aroK and aroL genes to cut off the metabolic flux, thus accomplishing the accumulation of shikimic acid. Besides, a non-phosphorylated pathway, that is, glk and glf genes (mainly by glk-glf integration into the ptsG locus) is introduced to enhance glucose utilization. To achieve the goal above-mentioned, we totally constructed 26 parts this year. See table below: | ||
| + | {| | ||
| + | | <html><img style="width:400px" src="https://static.igem.wiki/teams/4891/wiki/parts/22.png" ></html> | ||
| + | |- | ||
| + | |} | ||
<!-- --> | <!-- --> | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
Latest revision as of 15:13, 9 October 2023
sgRNAldhA
It is the key part that is responsible for optimizing metabolic network of the E. coli MG1655. Complicated metabolic flux usually leads to the inefficient production performance. With the disruption of the byproducts, intracellular PEP availability could be improved.
Usage and Biology
We engineered the shikimate pathway of E. coli MG1655 to efficiently accumulate SA. We knocked out ptsG, ldhA, adhE, poxB, and pta genes to achieve the production of precursor substance PEP. To increase intracellular E4P content, we overexpressed tktA and talB genes. To enhance product accumulation, we overexpressed aroG, aroB, aroD, and aroE genes, while knocking down aroK and aroL genes to cut off the metabolic flux, thus accomplishing the accumulation of shikimic acid. Besides, a non-phosphorylated pathway, that is, glk and glf genes (mainly by glk-glf integration into the ptsG locus) is introduced to enhance glucose utilization. To achieve the goal above-mentioned, we totally constructed 26 parts this year. See table below:
|
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]